Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France Leads Europe In Reimbursing Truvada For HIV Prophylaxis

This article was originally published in Scrip

Executive Summary

Gilead Sciences' HIV drug Truvada is now being reimbursed in France for pre-exposure prophylaxis (PrEP) under a "temporary use recommendation" (RTU) that came into effect on Jan. 4. This is understood to be the first European country where Truvada can be officially prescribed and reimbursed for PrEP, an indication for which it has not yet received an EU marketing authorization.

You may also be interested in...



Truvada Sales To Rise On EU Okay In HIV Prevention; UK Use Uncertain

The EU’s approval of Gilead’s Truvada for pre-exposure prophylaxis makes it the first medicine licensed in Europe to reduce the risk of HIV transmission through sexual intercourse and puts pressure on Britain’s reluctant, cash-strapped National Health Service to provide public funding for the drug’s preventative use.

Hepatitis C And PrEP Bring More Funding Headaches For NHS England

Drugs for hepatitis C and HIV prevention are causing funding problems for the NHS in England as court battles loom and innovation continues to bring more cost pressures.

UK To Go Ahead With Pre-Licensing Use Of COVID-19 Vaccines

A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded. 

Topics

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel